A anvisa aprovou o uso o do Medicamento Mounjaro, dafarmacêuticalilly, para tratamento da obesidade e sobrepeso, no di di di di di di di de junho. Antes Autorizado anas para diabetes tipo 2, oremédio, à base de tirzepatida, passou a ser Prescribeto para para para perda de peso em pessoas comíndice de Massa corporate (imc) acima de 30 kg/m² Decisão Ampliao uso das chamadas “canetas emigrecedoras”, grupoquejápanduiozempic, wegovy e saxenda. opreçodo movunjaro varia entre r $1700,000 r $2400,000.
Senior News Analyst & National Affairs Writer
Prabhat Sharma is a veteran journalist with over 12 years of experience covering national news, current affairs, and breaking stories across India. Known for his analytical approach and in-depth reporting, Prabhat brings clarity to complex topics and delivers content that informs, educates, and empowers readers.
He is passionate about political transparency, policy analysis, and the evolving landscape of Indian journalism.
When he’s not writing, you’ll find him reading non-fiction, watching documentaries, or exploring offbeat destinations
